Search Results 71-80 of 13193 for Tyrosine
This medication inhibits tyrosine hydroxylase, which is the rate-limiting step in catecholamine synthesis. Metyrosine should be considered if a patient has ...
The purpose of this study is to determine the effetiveness and safety of brepocitinib (a tyrosine kinase [TYK] 2/Janus kinase [JAK] 1 inhibitor) in patients ...
... tyrosine kinase inhibitors. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or ...
It is also given to adults and children with Ph+ CML in chronic phase (CP) or accelerated phase (AP) who have taken other medicines (eg, imatinib, tyrosine- ...
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus ...
Cell signaling in G protein-coupled and tyrosine kinase receptor systems. Mechanisms of novel targeted cancer chemotherapeutics. Molecular biology of ...
Ongoing studies show that p120 tyrosine phosphorylation correlates with aggressiveness of brain cancers, and that restoration of PLEKHA7 function inhibits ...
This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...
... tyrosine kinase inhibitor therapy. A Study to Evaluate 68Ga- PSMA-Dual Contrast PET/MRI and PET/CT for Hepatocellular Carcinoma Rochester, MN. The purpose of ...
... tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 months, after first-line AML therapy.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.